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ABSTRACT 
 
Oxaliplatin is a third generation anticancer drug that has proven to be successful 
in fighting ovarian and testicular cancer.  We are interested in determining how 
oxaliplatin and oxaliplatin derivatives interact with proteins, as well as how that 
interaction is affected by the size and shape of these platinum compounds.  We have 
synthesized oxaliplatin as it is used in cancer treatment, as well as similar platinum 
compounds with the same diaminocyclohexane ligand as oxaliplatin but with additional 
bulk added to the nitrogen atoms.  We are reacting oxaliplatin with key amino acids, 
including methionine, and will be comparing the kinetics of this reaction, as well as the 
adducts formed in the reaction, with the bulkier oxaliplatin derivative. 
 
 
Keywords: oxaliplatin, platinum (II) compounds, anti-cancer drugs, cisplatin, nuclear 
magnetic resonance 
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With almost 12,000,000 people in the United States having been diagnosed with some 
form of cancer, as of 2008, there is really no question as to why cancer treatment has 
been a very popular field of research in many scientific disciplines (
encompasses more than 200 diseases, each with different detection capabilities, growth 
rates, and abilities to spread.  It is caused by genetic alterations due to genetics, 
environmental factors and lifestyle choices (
include surgery, radiation therapy, and chemotherapy
cancer drugs.”  One of the first and most widely
cis-diamminedichloroplatinum(II)
 
 
Figure 
The cancer-fighting ability of platinum(II)
discovered by accident in 1965 by the Rosenbe
when it was observed that the electrolysis of platinum of electrodes generated a platinum 
complex that inhibited binary fission in Escherichia coli (E. coli) bacteria.  This platinum 
complex was found to be 
1
CHAPTER 1 
 
INTRODUCTION 
1).  Cancer 
2).  Current methods of treating cancer 
, which is treatment using “anti
-used anti-cancer drugs was cisplatin, or 
. 
 
1.  cis-diamminedichloroplatinum(II), or cisplatin. 
-containing compounds was first 
rg group at Michigan State University, 
cis PtCl2(NH3)2, or cisplatin.  The complex was then tested and 
-
 1
proved greatly effective in reducing sarcomas in rats(3).  As a result of this serendipitous 
finding, cisplatin was developed and approved by the FDA for use in the treatment of 
cancer in December 1978 (4).  While cisplatin was found to be very successful in treating 
testicular and ovarian cancer, there are many disadvantageous side effects associated with 
the drug and often led to nausea and vomiting, as well as peripheral neuropathy 
experienced by patients  In addition, high levels of nephrotoxicity are associated with 
cisplatin(5).  These high levels of toxicity are thought to be a result of the formation of 
adducts between platinum and DNA, as well as adducts between platinum and proteins 
(6).  In response to these harmful side effects, scientists attempted to synthesize 
platinum(II) compounds with the same therapeutic effects of cisplatin but with lower 
toxicity.  As a result, the second generation anti-cancer drug carboplatin, or  cis-
diammine(1,1-cyclobutanedicarboxylato)platinum(II) was developed. Carboplatin is 
shown to react much more slowly than cisplatin and is known to form complexes with a 
longer stability-- two conditions to which its lower nephrotoxicity is attributed (7).   
 The third generation anti-cancer drug oxaliplatin and an analog of the drug are the 
focus of the current research described throughout this paper.  Oxaliplatin, or (R,R')-1,2-
diaminocyclohexaneplatinum(II) oxalate, was approved by the FDA for treatment of 
colorectal cancer and cisplatin-resistant tumors (8).  The compound consists of a highly 
stable diaminocyclohexane (dach) ligand that causes the compound to show a behavior 
that highly contrasts that of cisplatin or carboplatin, both of which also have ammine 
ligands but different leaving ligands.  The reason for this is the inability for the dach 
ligand to be released from the platinum atom due to its higher stability caused by chelate 
 effect (7); the trans amine ligand in cisplatin and carboplatin can be displaced by the 
coordination of a sulfur atom. 
Figure 2.  (R,R')
 
 Platinum(II) compounds are known to form adducts with nucleobases of DNA 
and form crosslinks between adjacent nucleobases.  These compounds are known to bind 
to the N7 of guanine in particular.  In addition, platinum(II) c
affinity for sulfur groups, which are often used as "rescue agents" in chemotherapy
meaning they reduce binding to certain biomolecules and therefore reduce certain toxic 
side effects (7, 9).   The cytotoxicity of these anti
caused by reactions between the platinum compounds and proteins and peptides, which 
leads to the formation of Pt
shown to activate DNA damage recognition proteins, which eventually leads to 
apoptosis, or programmed cell death 
with DNA, it is essential to study the reactivity of the compounds with sulfur
proteins and peptides.  Because platinum has a high affinity for sulfur and methionine is 
one of two sulfur-containing amino acids, methionine is the main target for platinum 
interactions with proteins. 
Figure 3.  N-Acetyl
2
 
 
-1,2-diaminocyclohexaneplatinum(II) oxalate , or oxaliplatin
ompounds have a high 
-cancer compounds is thought to be 
-DNA adducts on adjacent guanines.  This adduct formation is 
(8).  Since cisplatin reacts more with proteins than 
 
  
-Methionine, a derivative of the amino acid methionine
 
, 
-containing 
 
  It is for this reason that a study of the reactivity of both oxaliplatin and the analog 
(R,R’)-1,2-dimethyl-diamminocyclohexaneplatinum(II) with the amino acid methionine, 
which contains a thioether group and is one of two amino acids containing a sulfur atom.  
An area of interest for future work 
glutathione, a sulfur-containing peptide.
 In a study done by Heudi et al. on the reactions of oxaliplatin and carboplatin with 
L-methionine, in contrast to cisplatin, it was shown that carboplatin formed the same five 
methionine-platinum adducts, which is sugg
cisplatin in the presence of sodium chloride.  Since oxaliplatin contains the dach ligand, a 
different amine ligand, this same transformation to cisplatin does not occur (
It is thought that oxaliplatin's lower toxicity can be attributed to its preferential 
reaction with L-methionine rather than guanosine.   In addition, the diaminocyclohexane 
ligand of oxaliplatin is highly stable and has the 
conformations, including the boat, twist, and chair conformati
the flexible cyclohexane ring
primary form.  After oxaliplatin coordinates to DNA, the 
to the molecule rather than being released such as in cisplatin and carboplatin. 
Figure 4.  The structure of 
3
is the reaction between the two compounds and 
 
estive of carboplatin transforming into 
ability to form a wide range of 
ons due to the presence of 
, with the chair conformation being the most stable and 
diamine ligand remains attached 
 
(R,R)-N,N’-dimethyl-1,2-diaminocyclohexaneplatinum oxalate 
[Pt(Me2dach)(ox)]. 
6).  
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In our studies, we have used a variety of different techniques to arrive at our 
results, including inorganic synthesis, Nuclear Magnetic Resonance (NMR) spectroscopy 
for characterization and kinetics studies, and High Performance Liquid Chromatography 
(HPLC) for purification of the oxaliplatin analog. 
 NMR spectroscopy is an essential tool in studying the structure of a molecule.  In 
the research project described, 1H NMR spectroscopy is used to characterize the 
synthesized compounds, as well as monitor the kinetics of experiments with methionine.   
1H NMR spectroscopy gives a separate signal for each hydrogen atom in a compound, 
allowing for an accurate assignment of position for each hydrogen atom based on known 
chemical shifts characteristic of a certain proton interaction.  1H NMR spectroscopy is 
also very useful in studying the kinetics of an experiment, as a spectrum can show you 
signals of hydrogens from both the reactants and the products of a reaction.  Any signals 
displayed in a spectrum that are not characteristic of the reactant are product signals—as 
such, you can observe the decrease in the concentration of reactants and subsequent 
increase in the concentration of product.  The rate of reaction can be monitored by 
examining the decrease of the signal of the reactant and the increase of the product signal. 
 High Performance Liquid Chromatography is a common technique for the 
separation and purification of compounds based on polarity.  A reverse-phase HPLC 
column, as used in the described studies to separate isomers,  consists of a non-polar 
stationary phase and a polar mobile phase.  A non-polar compound will require more 
time to elute from the column, whereas a polar compound will elute more quickly.  For 
cases, such as this, a concentration gradient is used in which both water and a polar 
 5
solvent are used as the mobile phase, gradually increasing the concentration of the polar 
solvent in order to gradually elute the more polar compounds from the column.    
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CHAPTER 2 
 
EXPERIMENTAL METHODS 
 
Synthesis and characterization of Pt(dach)(ox).  In order to synthesize 
oxaliplatin, a mixture of 64 mg liquid diaminocyclohexane ligand and 5 mL of methanol 
were added dropwise to a mixture of 232 mg potassium tetrachloroplatinate and 5 mL 
deionized water until a color change to yellow was absorbed and a precipitate was 
formed.  The reaction yielded 128.8 mg of Pt(dach)Cl2 .  64.8 mg of the Pt(dach)Cl2   was 
then reacted with 51.8 mg of silver oxalate to yield 27.9 mg of oxaliplatin, the identity of 
which was confirmed by 1H NMR in D2O using a 500 MHz JEOL Eclipse instrument.   
Synthesis and characterization of Pt(Me2dach)(ox). Pt(Me2dach)(Cl2) was then 
synthesized by adding dropwise 56.8 mg Me2dach in 5.0 mL methanol to 166 mg 
potassium tetrachloroplatinate in 5.0 mL deionized water and stirring for a minimum of 2 
hours.  The product was then converted to Pt(Me2dach)(ox) by reacting 100 mg of 
Pt(Me2dach)(Cl2) with 75 mg silver oxalate in 35 mL deionized water.  The reaction 
stirred overnight and was then filtered and dried. The reaction yielded 72.2 mg of 
Pt(Me2dach)(ox), which was confirmed by NMR using the same method as the 
Pt(dach)(ox) .  NMR and mass spectrometry also confirmed a mixed isomer form of the 
product.  
 7
 
 
 
Purification of Pt(Me2dach)(ox).  The mixed isomer form of the Pt(Me2dach)(ox) 
compound was separated using HPLC.  The separation was first tested using an analytical 
column and it was found that the isomers could be separated using a gradient of water 
and methanol.  The separation of the compound was then performed on an apHera C18 
Polymer HPLC column (25 cm x 4.6 mm x 5 µm) using a Hitachi Lachrom Elite system. 
A concentration gradient of water and methanol was used in 80:20 water:methanol for 1-
20 min., 40:60 for 20-21 min., and 80:20 for 22 minutes and beyond, each at a flow rate 
of 0.500 mL/min. 
Reaction of Pt(dach)(ox) and N-Ac-Met.  The kinetics of the reaction of 
Pt(dach)(ox) and N-Ac-Met were monitored in a 2:1 N-Ac-Met:Pt(dach)(ox) ratio in D2O 
using a 500 MHz JEOL Eclipse instrument.  The reaction was monitored over a 12-hour 
period and sporadically throughout the week to ensure no further activity had occurred. 
Reaction of Pt(Me2dach)(ox) and N-Ac-Met.  The kinetics of the reaction of a 
mixed isomer form of Pt(Me2dach)(ox) and N-Ac-Met were monitored in the presence of 
excess N-Ac-Met using the same method as the reaction with Pt(dach)(ox).  Excess N-
Ac-Met was used due to uncertainty regarding the stoichiometry of the impure isomer.  In 
Figure 5.  Reaction mechanism for synthesis of Pt(Me2dach)(ox). 
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the near future, reactions of N-Ac-Met and a pure isomer of Pt(Me2dach)(ox) will be 
studied. 
 The NMR spectra of the Pt(
synthesized confirmed the correct identity of the product.  The NMR spectrum of 
Pt(Me2dach)(ox) is shown below in Figure 6
Figure 
 
NMR results suggest
isomers, as noted by the two 
synthesis of Pt(Me2dach)(o
9
CHAPTER 3 
 
RESULTS 
 
dach)(ox) and Pt(Me2dach)(ox) compounds that were 
.  
 
6.  1H NMR spectra of Pt(Me2dach)(ox). 
 that the synthesis of Pt(Me2dach)(ox) yielded
singlet peaks occurring at approximately 2.5 ppm
x) is capable of yielding multiple isomers, because the 
 at least two 
. The 
 addition of the methyl groups t
centers, which allows for the possibility of several different stereochemistries.  In this 
case, the Pt(Me2dach)(ox) can be in
These configurations arise due to the chirality of the compounds and describe the 
stereochemistry occurring at the amine nitrogens and the carbons 
respectively. In order to accurately 
isomerically pure form of the compound be obtained. To achieve this, the compound was 
separated using HPLC chromatography.
of the Pt(Me2dach)(ox) compound.
 
Figure 
10
o the amine nitrogens in the dach ligand creates two chiral 
 (S,R,R,S), (S,R,R,R), or (R,R,R,R) configurations
at N, C, C, and N, 
test the kinetics of Me2DachOx, it is necessary that an 
 Figure 7 shows the HPLC data for the separation 
 
7.  HPLC chromatogram of Pt(Me2dach)(ox) . 
.  
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As evident in the HPLC spectra, there was a very clear resolution between the two 
peaks, which suggest the elution of two isomers with different polarities, with 
approximately 7 minutes between the elution of each potential isomer. The isomers were 
then collected in separate vials until enough was obtained for experimental use 
(approximately 3 mg) and then a small sample was characterized by NMR spectroscopy 
to determine which isomer was the most pure and thus the best for reaction with N-Ac-
Met.   The NMR spectra of each HPLC peak is shown in Figures 8 and 9 below.  
 Figure 8.  1H NMR spectrum of first peak obtained from HPLC separation of 
Figure 9.  1H NMR spectrum of second peak obtained from HPLC separation of 
The NMR spectra of the product collected from the major peak, occurring at 
approximately 7 minutes in the HPLC chromatogram,
the first elution is the most pure
12
Pt(Me
 
Pt(
 suggests that the collection
, due to the presence of only one singlet signal 
 
2dach)(ox). 
Me2dach)(ox). 
 from 
at 
 approximately 2.5 ppm, and is 
spectrum of the second peak eluted at approximately 13 minutes shows two singlet 
signals at approximately 2.5 ppm, suggesting a mixed isomer form.
this product then be used to study the kinetics of the reaction between Pt(Me
and N-Ac-Met, however mechanical issues with the NMR equipment prevented the 
experiment from taking place.  Prior to the purification, a kinetics experiment was 
performed with impure Pt(Me
The NMR study of the rea
Figure 10. Column 1 shows the r
minutes, respectively where  a) unreacted S
N-Ac-Met.  Column 2 shows the r
250 minutes, respectively where  a) unreacted S
Though the data obtained from the experiment is not as conclusive as results 
yielded from a pure isomer, the data does suggest that no significant change in the 
kinetics of the reaction aft
13
thought to be of the (S,R,R,S) configuration
  It was intended that
2dach)(ox) and excess N-Ac-Met for preliminary results. 
ction is shown below in Figure 10.   
 
eaction of oxaliplatin with N-Ac-Met over the span of 10, 100, and 250 
-CH3 of N-Ac-Met, b) acetyl-methyl product, and c) unreacted 
eaction of Pt(Me2dach)(ox) with N-Ac-Met over the span of 10, 100, and 
-CH3 of N-Ac-Met, b) acetyl-methyl product, and c) 
unreacted N-Ac-Met. 
er the addition of bulk (a larger, more sterically hindered 
.  The NMR 
 
2dach)(ox) 
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group) to the amine nitrogens of oxaliplatin.  The NMR spectra above show the reaction 
of oxaliplatin with N-Ac-Met and the reaction of Pt(Me2dach)(ox) with N-Ac-Met at 10, 
100, and 250 minutes, respectively.  The NMR shows that the increase of the acetyl-
methyl product signal, labeled b. and subsequent decrease of unreacted N-Ac-Met do not 
vary greatly between the two reactions.  Both reactions completed within approximately 
three hours.  The NMR spectra does suggest that the reaction of N-Ac-Met with 
Pt(Me2dach)(ox) is faster, however this is due to the reaction with Pt(Me2dach)(ox) being 
in the presence of excess N-Ac-Met.  More conclusive data will be obtained once the 
reaction is performed with an isomerically pure form of Pt(Me2dach)(ox). 
 The NMR spectra above for the kinetics experiment of oxaliplatin and N-Ac-Met 
do not show the signal for S-CH3 resonance anticipated in the product. As the amount of 
product in the sample increased, the S-CH3 signal should shift due to the coordination of 
the sulfur atom to the platinum atom of oxaliplatin. Since this was not observable, we 
suspected that our sample had multiple conformations in intermediate exchange, which 
broadened the NMR signal.  Increasing the temperature of the sample can circumvent the 
effect of intermediate exchange, because the rate of exchange increases as temperature 
increases.  In order to confirm that the product yielded the anticipated S-CH3 peak, a 
variable temperature experiment was a 1H NMR spectra of the product was taken at 
40°C, 60°C, and 80°C and the results are shown below in Figures 11, 12, and 13, 
respectively.  
 Figure 11.  1H NMR spectrum of product of kinetics reaction of N
 
Figure 12.  1H NMR spectrum of product of kinetics reaction of N
15
 
-Ac-Met and oxaliplatin at 40
 
-Ac-Met and oxaliplatin at 60
°C. 
°C. 
 Figure 13. 1H NMR spectrum of product of kinetics reaction of N
 The NMR spectra above clearly show that increasing the temperature 
sample sharpened the signal and revealed the S
CH3 signal shifted from approximately 2.1 ppm in the unreacted S
Figure 10, peak a. to approximately 2.5 ppm
product. 
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-Ac-Met and oxaliplatin at 80
-CH3 partner signal of the sample.  
-CH3 peak as shown in 
, was suggests this is the S-CH
°C. 
of the 
The S-
3 signal of the 
  
Initial results of the kinetics experiences comparing the reactivity of oxaliplatin 
and Pt(Me2dach)(ox) with N
methyls to the amine nitrogen found in oxaliplatin has no significant 
of the reaction.  Both the reaction of oxaliplatin and Pt(Me
finished in approximately three hours.  
previous research (10) has shown that the addition of bulk to similar platinum compounds 
has had a tremendous affect on the reactivity with sulfur
study, the addition of two methyls to the two amine nitrogens in platinum ethylen
dinitrate resulted in a vast decrease in the rate constant in the reaction with N
5’-GMP, as well as a significant decrease in the rate constant with Guanosine compared 
to the original compound with no bulk added.  
Figure 15.  Platinum
17
CHAPTER 4 
 
DISCUSSION 
-Ac-Met suggest that the addition of bulk in the form of two 
effect
2dach)(ox) with N
This is an interesting finding, consi
-containing ligands.  In this 
 
 ethylenediamine dinitrate and tetramethylethylenediamine dinitrate.
 on the kinetics 
-Ac-Met 
dering 
ediame 
-Ac-Met and 
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Table 1.  En/Me4En rate constants for reactions with different sulfur-containing 
substrates. 
 Ratio of 
En/Me4En 
Rate Constants 
N-Ac-Met 16 
5’-GMP 13 
Guanosine 5.4 
 
This disparity in results between the experiments described above and the results 
of the previous experiment are at this time thought to be attributed to either the presence 
of a tertiary amine in the platinum ethylenediamine dinitrate as opposed to the secondary 
amine in Pt(Me2dach)(ox) or perhaps the difference between the nitrate leaving groups 
instead of the oxalate leaving group of oxaliplatin and Pt(Me2dach)(ox).  It is known that 
the oxalate leaving group is not released as easily as other leaving ligands due to its 
higher stability and the chelate effect (7).  
It is also interesting to note that in previous studies, experimental results 
suggested that the added bulk only coordinated to one methionine, suggesting the 
 19
formation of a mono product (10).  Experimental results shown from our work adding 
bulk to oxaliplatin suggest that the bulk coordinates to two methionines, suggesting the 
formation of a bis product.  A 195Pt NMR experiment was performed using the sample 
from the kinetics reaction of Pt(Me2dach)(ox) and methionine to determine whether a 
mono or bis product was formed.  The 195Pt NMR spectrum displayed a peak between -
3600 and -3800 ppm, a known characteristic of the PtN2S2 coordination environment, 
suggesting the formation of a bis product.  In the future, a second 195Pt experiment with 
the reaction of pure Pt(Me2dach)(ox) and N-Ac-Met will be performed to determine if a 
bis product is also formed in this case.   
Future work includes continuing to purify Pt(Me2dach)(ox) in quantities sufficient 
for kinetics studies with N-Ac-Met, as well as other sulfur-containing biological ligands, 
as well as using NMR to determine the conformation of the isomerically pure form of 
Pt(Me2dach)(ox) and using 195Pt NMR to determine whether a bis or mono product is 
formed in the reaction with N-Ac-Met. 
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